Exelixis, Inc. (EXEL)

Acerca de Exelixis, Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Al 3 de noviembre de 2026, la acción de Exelixis, Inc. (EXEL) subió con fuerza a $73.19, un alza de 4.36% (+$3.06) frente al cierre anterior. En la sesión, las acciones han operado entre $70.11 y $73.30. Eso ubica a EXEL cerca del máximo de su rango de 52 semanas, de $37.58 a $73.30. Exelixis, Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $17.11 mil millones, con cerca de 1.20 millones de acciones negociadas.

Últimas noticias de EXEL

• Exelixis (EXEL) International Revenue in Focus: Trends and ExpectationsYahoo Finance· 2 nov, 8:15 a.m. ET
• Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)Yahoo Finance· 31 oct, 8:08 a.m. ET
• Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?Yahoo Finance· 31 oct, 12:20 a.m. ET
• EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesYahoo Finance· 30 oct, 11:46 a.m. ET
• Exelixis (EXEL) Q3 2026 Earnings Call Transcriptfool.com· 30 oct, 11:00 a.m. ET
• Exelixis, Inc. Q3 2026 Earnings Call Summaryapp.moby.co· 30 oct, 8:30 a.m. ET
• What Exelixis (EXEL) Said on Its Q3 Earnings Callmarketbeat.com· 29 oct, 8:14 p.m. ET
• Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesYahoo Finance· 29 oct, 5:00 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de EXEL en un solo lugar? Crea una cuenta gratis →

• $EXEL monster breakout

  @cfromhertz· 3 nov, 12:15 p.m. ET

• $EXEL $MRK we’ll take $125 BO offer 😉

  @DefenseMania· 3 nov, 10:01 a.m. ET· Alcista

• @ValuJack yeah that 117 vs 69 gap is the part that sticks with me imo on $EXEL. a 1B buyback plus generics blocked to 2030 gives it runway, and that March decision is the next gate. is March the real mover here, or does the buyback keep doing the work til then. the money on th…

  @BiotechSwings· 3 nov, 12:41 a.m. ET

• $EXEL Exelixis came up in our momentum screen today. Up almost 80% in a year, but our fair value estimate is still about $117 vs a price around $69. What stands out: sales up 10% last quarter, earnings beat, and they've bought back $1B of their own shares this year. A cour…

  @ValuJack· 2 nov, 3:26 p.m. ET

• Looks like industry is pivtoing to basic neccessities and health $EXEL $PG $REPL $CL $KMB Better sense may prevaill

  @victorgn· 2 nov, 11:02 a.m. ET· Alcista

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →